RxDoctor Payments Data

Mandi Benton, APRN

Adult Health · Honolulu, HINPI 1154630473

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 93 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by Abbott at 30.2% of the total.

$3,923in general payments, 2019–2025

Across 93 payments — averaging $42.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$1K
  • Boehringer Ingelheim$835
  • Merck$423
  • Abiomed$325
  • Pfizer$259
  • Alnylam Pharmaceuticals Inc.$204
  • plus $691 from 11 others

What the payments were for

  • Food & beverage$3,923100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,923 in reported general payments places this provider in the 85th percentile of 44 adult health providers in Hawaii.

See all adult health providers in Hawaii

Medicare billing

Part B allowed, 2024
$7,398
Medicare patients
35
Services billed
53

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis41$920,387
EntrestoSacubitril/Valsartan140$160,408
JardianceEmpagliflozin88$137,400
EliquisApixaban47$68,235
FarxigaDapagliflozin Propanediol11$18,475
XareltoRivaroxaban11$15,552
Atorvastatin Calcium107$3,409
Metoprolol Succinate104$1,717
Eplerenone12$959
Carvedilol55$835
Bumetanide21$767
ClopidogrelClopidogrel Bisulfate25$596
Digoxin21$496
Spironolactone63$467
Losartan Potassium33$368

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$259$988,62288 claims
Boehringer IngelheimJardiance$835$137,40088 claims
AstraZenecaFarxiga$19$18,47511 claims
Johnson & JohnsonXarelto$45$15,55211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 44 adult health providers in Hawaii.

Other adult health in Honolulu

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →